Drug Research
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing
Roche announced that Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration. Bringing together the companies' expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens...
Drug Research
FDA Grants Roche Tina-qant Lp Assay Breakthrough Device Designation – a key marker for hereditary cardiovascular risk
Roche announced that the Tina-quant® lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. FDA to identify patients who may benefit from innovative Lp(a)-lowering therapy currently in development. Lp(a) is emerging as an important, yet under-recognised,...
Drug Research
Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines
Eli Lilly and Company announced that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion. This expansion will...
Drug Research
Novo Nordisk invests ¥4 B in China for sterile preparation expansion project
Novo Nordisk has announced that it would invest approximately 4 billion yuan (¥) in Tianjin for a sterile preparation expansion project and recently held a groundbreaking ceremony for the expansion project.
On the day of the event, leaders from the...
Drug Research
WuXi AppTec breaks ground on new R&D and manufacturing site in Singapore
WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has announced the groundbreaking of its new R&D and manufacturing site in Singapore.
This milestone,...
Drug Research
AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore
AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a...
Drug Research
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.